Landscape of new drugs and targets in inflammatory bowel disease
Abstract
Although the therapeutic armamentarium of Inflammatory bowel diseases (IBD) physicians has expanded rapidly in recent years, a proportion of patients remain with a suboptimal response to medical treatment due to primary no response, loss of response or intolerance to currently available drugs. Our growing knowledges of IBD pathophysiology has led to the development of a multitude of new therapies over time, which may, 1 day, be able to address this unmet medical need. This review aims to provide physicians an update of emerging therapies in IBD by focusing on drugs currently in phase 3 clinical trials. Among the most promising molecules are anti-IL-23, JAK-inhibitors, anti-integrins and S1P modulators. While the results in terms of efficacy and safety are fairly clear for some classes, the question of safety remains more uncertain for other classes. Molecules at a more preliminary stage of development (phase 1 and 2), one of which may 1 day offer an optimal benefit-risk ratio, will also be presented as well as their respective mechanisms of action.
Related
- HLA allele DRB1*01:03: the genetic link to neutralizing IL-10 antibodies in inflammatory bowel disease
- Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.
- Identification of a shared PAX5-mediated B-cell regulatory axis in inflammatory bowel disease and rheumatoid arthritis
- Serum proteins predict incident inflammatory bowel disease 14 years before diagnosis: a machine-learning and Cox modelling in the UK Biobank
- The role of metabolic crosstalk between Intestinal epithelial cells and immune cells in inflammatory bowel disease and targeting strategies
BibTeX
@article{vieujean2026landscape,
title = {{Landscape of new drugs and targets in inflammatory bowel disease}},
author = {Sophie Vieujean and Ferdinando d'Amico and Patrick Netter and Silvio Danese and Laurent Peyrin-Biroulet},
journal = {United European Gastroenterology Journal},
year = {2026},
month = sep,
doi = {10.1002/ueg2.12305},
url = {https://hal.univ-lorraine.fr/hal-04167949v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Landscape of new drugs and targets in inflammatory bowel disease
AU - Sophie Vieujean
AU - Ferdinando d'Amico
AU - Patrick Netter
AU - Silvio Danese
AU - Laurent Peyrin-Biroulet
PY - 2026
DA - 2026/09/17
JO - United European Gastroenterology Journal
DO - 10.1002/ueg2.12305
UR - https://hal.univ-lorraine.fr/hal-04167949v1
AB - Although the therapeutic armamentarium of Inflammatory bowel diseases (IBD) physicians has expanded rapidly in recent years, a proportion of patients remain with a suboptimal response to medical treatment due to primary no response, loss of response or intolerance to currently available drugs. Our growing knowledges of IBD pathophysiology has led to the development of a multitude of new therapies over time, which may, 1 day, be able to address this unmet medical need. This review aims to provide physicians an update of emerging therapies in IBD by focusing on drugs currently in phase 3 clinical trials. Among the most promising molecules are anti-IL-23, JAK-inhibitors, anti-integrins and S1P modulators. While the results in terms of efficacy and safety are fairly clear for some classes, the question of safety remains more uncertain for other classes. Molecules at a more preliminary stage of development (phase 1 and 2), one of which may 1 day offer an optimal benefit-risk ratio, will also be presented as well as their respective mechanisms of action.
SN - 2050-6406
SN - 2050-6414
ER -